Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Tenax Therapeutics announced additional data from its Phase 3 LEVEL trial evaluating oral levosimendan (TNX-103) in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). While primary endpoints on exercise capacity were not met, subgroup analysis revealed significant improvements in patients with low…
PagSeguro trades at bargain multiples despite mid-single-digit to double-digit revenue growth and margin stability. Elevated short interest and macro worries have pushed the stock below fair-value levels; we see a disciplined long with a $12.50 target and $7.50 stop over a 180 trading-day horizon.
Stevanato Group looks set to benefit from product validation that connects its glass containment business to higher-margin delivery devices. The technical picture is mixed, but the combination of market tailwinds for injectable formats, a $5.75B market cap and manageable float create a tradeable risk-reward. This plan lays out an entry at $21.00, a…
Apple’s modest margin guidance has rattled short-term sentiment, but the underlying cash flow, product cadence and on-device AI roadmap justify a mid-term long. Trade plan with entry at $320.13, stop at $300.00, and target of $360.00 over ~45 trading days.
Morningstar is a cash-generative, data-heavy franchise trading at about $8.2B market cap with double-digit returns on equity and solid free cash flow. After a sharp derating earlier this year, the stock looks set for a 15% recovery with room to climb if revenue mix and PitchBook monetization continue to improve. This trade lays out an entry, stop, …
SBIT (ProShares UltraShort Bitcoin ETF) offers a direct way to express a bearish view on Bitcoin via -2x daily exposure. Technicals show the fund trading below all major moving averages with bearish MACD and an oversold RSI, while market activity and distribution yield create an asymmetric entry opportunity. This trade idea lays out an actionable l…
Nova (NVMI) sells specialized metrology tools and software to chipmakers. Strong Q2 2025 revenue momentum, rising demand tied to AI infrastructure, and a photonics tailwind make NVMI a multi-engine compounder. The stock is extended from its highs but is showing oversold technicals and heavy short interest — a disciplined entry at $349.25 with a $29…
Nano Labs (NA) trades cheaply on a market cap of roughly $51.9M despite owning AI chip IP, a 70,000 BNB strategic reserve and recent product launches. H1 2026 crypto fair-value losses cratered earnings, but those are non-operating swings that may reverse if the company executes its AI pivot. Heavy short interest and low float amplify both upside an…
Centrica is in the middle of a multi-year transformation from a legacy UK gas-and-services provider to a more integrated power and customer-energy solutions company. I see asymmetric upside if management executes on asset rationalization, cost-out and growth in power/renewables; enter at $1.25, stop at $0.95, target $1.90 over the next 180 trading …
Texas Instruments looks positioned to benefit from a broad analog and embedded processing upcycle driven by industrial automation, automotive electrification, and higher-margin data center demand. Combine strong recent operating performance with a pullback from the June highs and the stock becomes an actionable long with clearly defined risk-reward…
Early on Aug. 29, mutinous soldiers launched coordinated attacks on Niamey’s airport and the presidential palace, producing hours of gunfire and explosions and briefly taking state radio and television off the air. By late morning the defence ministry said loyalist forces were gradually retaking seized sites, but security sources reported mutineers…
Bitcoin slipped under $78,000 after climbing above $81,000 earlier in the week, as data show its 90-day correlation with gold has risen markedly while its link to the Nasdaq 100 has weakened. On-chain metrics indicate little selling from the oldest holders, while macro factors such as U.S. federal debt topping $40 trillion and renewed 'debasement' …
Guardian Metal Resources (GMTL) is a mid-tier junior sitting on multiple Nevada tungsten projects. The market is pricing in a two-speed outcome: a near-term rerating driven by rising tungsten prices and critical-minerals urgency, and a longer construction timeline that requires capital and permits. This trade idea outlines an entry at $12.80, a sto…
CVB Financial (CVBF) just closed its merger with Heritage Commerce, creating a $20B-plus California-focused franchise and adding 16 Bay Area branches. The combination should accelerate loan growth, diversify deposit mix, and support earnings-per-share through cost and revenue synergies. At $22.19, CVBF offers a roughly 3.6% yield, reasonable valuat…
Braemar Hotels & Resorts (BHR) trades at a tiny market cap relative to enterprise value and carries discounted multiples that can re-rate if the company completes its self-management transition, executes cost-savings and avoids a large change-of-control payment. This trade idea proposes a mid-term long entry at $2.03 with a $3.20 target and $1.70 s…
China's extensive crude inventories, built up over recent years, have enabled Beijing to sharply cut oil imports amid the Iran war. The stockpiles - estimated between 1 billion and 1.4 billion barrels - provided roughly 120 days of import cover and supported a 23% decline in crude arrivals between March and July versus the prior year. At the same t…
Occidental Petroleum's recent portfolio simplification and cash inflows have materially improved leverage metrics and left the company trading at a single-digit P/E versus peers. With a market cap near $59B, EV/EBITDA of ~5.2x and a catalogue of catalysts ahead, a disciplined long trade with a clear stop offers asymmetric upside over the next 180 t…
Qualys trades at a premium multiple today but shows signs that a stronger product roadmap and sustained cloud-security demand could justify the valuation. This trade idea lays out a long entry, precise risk controls, catalysts to watch and the scenarios that would make us change our view.
G Mining (GMINF) is trading near $38.43 with a $11.40B market cap and a P/E of 24.8. Balance-sheet strength and recent operational scale-up position the company to pursue sizable expansion. Technicals are constructive and short interest is meaningful — a controlled long with a $50 target and $33 stop balances upside from expansion against execution…
Summit Midstream looks poised for a material re-rating as leverage comes down and EBITDA shows sequential improvement. With clear operational levers and identifiable catalysts, a controlled long trade offers a favorable reward-to-risk setup. Entry at $6.50, stop at $5.25, target at $9.25 over a 180 trading-day horizon.
Onto Innovation supplies metrology, inspection, lithography and yield-management tools that are becoming critical as AI chips scale. The stock has pulled back ~20% from its prior close and shows technical signs of a consolidation; we argue this is a buy-the-dip setup for a mid-term swing trade targeting higher multiple re-rating as customers priori…
Truist Financial and Fifth Third Bancorp have suspended distribution of insurance products connected to Delaware Life Insurance after a U.S. federal inquiry scrutinized affiliated loans on the insurer’s balance sheet. The probe has also stalled a proposed $10 billion investment led by Mubadala into Walter’s TWG Global and prompted ratings agencies …
20/20 BioLabs announced a rescheduled investor webinar to discuss its second quarter 2026 performance, highlighting record revenue growth from its multi-cancer early detection test, OneTest™. CEO Jonathan Cohen will detail the company's evolving test platform, successful state-funded cancer screening initiatives, and the strategic path toward regul…
Allogene trades like a binary biotech with limited upside priced in. Recent arbitration wins, durable responses from ALLO-316, and a $175M capital raise create a window where upside from commercialization or partnership of cema-cel could re-rate the stock. This trade idea lays out a long position at $2.02 with clear stops, targets, catalysts and ri…
Septerna is an early-stage biotech focused on GPCR-targeted therapies. Clinical and translational data remain the key value drivers; with limited public financial detail available, the upside hinges on program validation, partnering potential, and platform durability. I am long and recommend an entry at $6.50 with a $15.00 target and a $3.50 stop f…
